NCT04768166View on ClinicalTrials.gov

Testing Miglustat Administration in Subjects With Spastic Paraplegia 11

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

August 30, 2021

Study Completion Date

September 15, 2021

Conditions

Hereditary Spastic Paraparesis

Interventions

DRUG

Miglustat 100 MG

100mg/TID in 4w then 200mg/TID in 8 w

Trial Locations (1)

56128

IRCCS Fondazione Stella Maris, Pisa

All Listed Sponsors

lead

IRCCS Fondazione Stella Maris

OTHER